A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)

Exclusion Criteria

• •Uncontrolled blood pressure, defined as systolic blood pressure \>180 millimeters of mercury (mmHg) and/or diastolic blood pressure \>100 mmHg while a patient is at rest on Day 1
• •Pregnancy or breastfeeding, or intention to become pregnant during the study
• •CNV due to causes other than AMD in the study eye
• •Any history of macular pathology unrelated to AMD affecting vision or contributing to the presence of intraretinal or subretinal fluid in the study eye
• •Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could either reduce the potential for visual improvement or require medical or surgical intervention during the study
• •Uncontrolled glaucoma in the study eye
• •Any prior or concomitant treatment for CNV or vitreomacular-interface abnormalities in the study eye
• •Prior IVT administration of faricimab in either eye
• •History of idiopathic or autoimmune-associated uveitis in either eye
• •Active ocular inflammation or suspected or active ocular or periocular infection in either eye